Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
暂无分享,去创建一个
Manesh R. Patel | K. Anstrom | C. O'connor | J. Rouleau | E. Braunwald | R. Kim | G. Felker | Manesh R Patel | Adrian F. Hernandez | J. Oh | D. Mann | L. Stevenson | M. LeWinter | R. Tracy | G. Lewis | C. O'connor | S. McNulty | S. Goldsmith | B. Borlaug | M. Redfield | B. Bart | D. Bull | E. Ofili | G. Lin | E. Velazquez | A. Mascette | M. Semigran | M. Givertz | Kerry L Lee | A. Deswal | Horng H. Chen | Jenny Ibarra | A. Hernandez | M. Patel | Horng H. Chen | J. Oh | for the RELAX Trial | G. Lewis
[1] P. Light,et al. Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.
[2] R. Arena,et al. Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.
[3] D. Kass,et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.
[4] A. C. Medeiros,et al. Effect of sildenafil in renal ischemia/reperfusion injury in rats. , 2010, Acta cirurgica brasileira.
[5] G. Lewis,et al. Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.
[6] Y. Chang,et al. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. , 2009, American journal of physiology. Renal physiology.
[7] B. Borlaug,et al. Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study". , 2012, Circulation.
[8] S J Jay,et al. Reference equations for the six-minute walk in healthy adults. , 2000 .
[9] D. Kass,et al. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. , 2009, Journal of molecular and cellular cardiology.
[10] M. Lauer,et al. Chronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol). , 2005, The American journal of cardiology.
[11] D. Delurgio,et al. Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.
[12] M. Packer,et al. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. , 2001, Journal of cardiac failure.
[13] E. Braunwald,et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. , 2012, American heart journal.
[14] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[15] M. Redfield,et al. Epidemiology of diastolic heart failure. , 2005, Progress in cardiovascular diseases.
[16] V. Froelicher,et al. Exercise standards. A statement for health professionals from the American Heart Association. , 1990, Circulation.
[17] Akshay S. Desai,et al. Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial , 2013, Circulation. Heart failure.
[18] P. Steendijk,et al. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure‐loaded right ventricle , 2012, European journal of heart failure.
[19] V. Froelicher,et al. Exercise standards. A statement for healthcare professionals from the American Heart Association. Writing Group. , 1995, Circulation.
[20] E. Braunwald,et al. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. , 2012, Circulation. Heart failure.
[21] William Stewart,et al. Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[22] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[23] R. Kronmal,et al. Left Ventricular Mass: Allometric Scaling, Normative Values, Effect of Obesity, and Prognostic Performance , 2010, Hypertension.
[24] R. Arena,et al. PDE 5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function , Cardiac Geometry , and Clinical Status in Patients With Stable Systolic Heart Failure , 2011 .
[25] Akshay S. Desai,et al. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. , 2010, Journal of cardiac failure.
[26] R. Arena,et al. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long‐term cardiopulmonary exercise testing placebo‐controlled study , 2012, European journal of heart failure.
[27] Amir Lerman,et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. , 2010, Journal of the American College of Cardiology.
[28] M. Guazzi,et al. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. , 2004, Journal of the American College of Cardiology.
[29] A. Feldman,et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. , 2006, Journal of the American College of Cardiology.
[30] J. Pedraza-Chaverri,et al. Sildenafil Treatment Prevents Glomerular Hypertension and Hyperfiltration in Rats with Renal Ablation , 2012, Kidney and Blood Pressure Research.
[31] R. Gerszten,et al. Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .
[32] Mark E. Anderson,et al. Sildenafil Prevents and Reverses Transverse-Tubule Remodeling and Ca2+ Handling Dysfunction in Right Ventricle Failure Induced by Pulmonary Artery Hypertension , 2012, Hypertension.
[33] Milton Packer,et al. Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.
[34] M. Pillinger,et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .
[35] W. Hundley,et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. , 2001, Journal of the American College of Cardiology.